You are here: Home Clinical Services Clinical Pathology Kristi J. Smock, M.D.
Kristi J. Smock, M.D.

Kristi J. Smock, M.D.

Phone: 583-2787 ext 2154

ARUP Laboratories

Faculty Assistant:   Leita Rogers  



  • Associate Professor of Pathology
  • Medical Director, Hemostasis/Thrombosis Laboratory, ARUP Laboratories
  • Associate Residency Program Director
  • Rotation Director for Coagulation Medicine Rotations

Scholarly Emphasis: Hemostasis/Thrombosis

Dr. Smock is currently an Associate Professor in the Department of Pathology at the University of Utah. She completed her residency and fellowship training at the University of Utah and is board certified in Anatomic and Clinical Pathology and Hematopathology. She has a particular interest in Coagulation Medicine and is Medical Director of the Hemostasis/Thrombosis Laboratory at ARUP where she enjoys being involved in all aspects of the laboratory. She particularly enjoys making contributions to patient care by consulting on difficult coagulation cases. She has additional clinical service responsibilities in Hematopathology, where she signs out bone marrow cases. Dr. Smock enjoys teaching and serves as the Associate Residency Program Director for the Department of Pathology. As Rotation Director for the resident and fellow rotations in Coagulation Medicine, she is actively involved in resident and fellow training, and she received the Outstanding Teaching Award in Clinical Pathology in 2010. Dr. Smock is also involved in teaching medical students at the University of Utah during their Hematology curriculum and serves on the Undergraduate Medical Education Committee for the Department of Pathology. She has many research interests in Coagulation Medicine including ongoing projects related to elevations of coagulation factors and association with thrombotic risk.

Selected Publications

  • 1.Herron MD, Vanderhooft SL, Smock K, Zhou H, Leachman SA, Coffin C (2004). Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohistochemical analysis. Am J Surg Pathol, 28(8), 1017-25.
  • 2.Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, Min DJ (2006). Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer, 47(2), 130-40.
  • 3.Smock KJ, Perkins SL, Bahler DW (2007). Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Arch Pathol Lab Med, 131(6), 951-5.
  • 4.Smock KJ, Nelson M, Tripp SR, Sanger WG, Abromowitch M, Cairo MS, Perkins SL (2008). Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children's Oncology Group. Pediatr Blood Cancer, 51(4), 489-94.
  • 5.Crist RA, Gibbs K, Rodgers GM, Smock KJ (2009). Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples. Lab Hematol, 15(4), 45-8.
  • 6.Smock KJ, Rodgers GM (2009). Laboratory identification of lupus anticoagulants. Am J Hematol, 84(7), 440-442.
  • 7.Smock KJ, Crist RA, Hansen SJ, Rodgers GM, Lehman CM (2010). Discard tubes are not necessary when drawing samples for specialized coagulation testing. Blood Coagul Fibrinolysis, 21(3), 279-82.
  • 8.Penmetsa GK, Rodgers GM, Smock KJ (2010). Avoiding errors in the laboratory evaluation of potent lupus anticoagulants. Am J Hematol, 85(4), 272-4.
  • 9.Smock KJ, Rodgers GM (2010). Laboratory evaluation of aspirin responsiveness. Am J Hematol, 85(5), 358-60.
  • 10.Sangle NA, Rodgers GM, Smock KJ (2011). Prevalence of heparin in samples submitted for lupus anticoagulant testing. Lab Hematol, 17(1), 6-11.
  • 11.Wilcox R, Pendleton RC, Smock KJ, Rodgers GM (2011). Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. Hosp Pract (Minneap), 39(3), 23-34.
  • 12.Smock KJ, Saunders PJ, Rodgers GM, Johari V (2011). Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. Am J Hematol, 86(12), 1032-34.
  • 13.Sangle NA, Agarwal AM, Smock KJ, Leavitt MO, Warnke R, Bahler D, Perkins SL (2011). Diffuse large B-cell lymphoma with aberrant expression of the T-cell antigens CD2 and CD7. Appl Immunohistochem Mol Morphol, 19(6), 579-83.
  • 14.Tantravahi SK, Williams LB, Digre KB, Creel DJ, Smock KJ, Deangelis MM, Clayton FC, Vitale AT, Rodgers GM (2012). An inherited disorder with splenomegaly, cytopenias, and vision loss. Am J Med Genet A, 158A(3), 475-81.
  • 15.Shirts BH, Rodgers GM, Smock KJ (2012). Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer. Thromb Res, 130(3), e134-8.
  • 16.Pandey S, Post SR, Alapat DV, Smock KJ, Post GR (2013). Prolonged prothrombin time correlates with serum immunoglobulin levels in patients with plasma cell dyscrasia. Int J Lab Hematol, 35, 421-27.
  • 17.Heikal NM, Smock KJ (2013). Laboratory testing for platelet antibodies. Am J Hematol, 88(9), 818-21.
  • 18.Heikal NM, Murphy KK, Crist RA, Wilson AR, Rodgers GM, Smock KJ (2013). Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events. Am J Clin Pathol, 140(5), 680-5.
  • 19.Smock KJ, Ledford-Kraemer MR, Meijer P, Hsu P, Van Cott EM (2014). Proficiency testing results for heparin-induced thrombocytopenia in north america. Semin Thromb Hemost, 40(2), 254-60.
  • 20.Hsu P, Zantek ND, Meijer P, Hayward CP, Brody J, Zhang X, Smock KJ, Van Cott EM (2014). Factor XIII Assays and Associated Problems for Laboratory Diagnosis of Factor XIII Deficiency: An Analysis of International Proficiency Testing Results. Semin Thromb Hemost, 40(2), 232-8.
  • 21.Smock KJ, Agarwal AM, Lim MS, Tripp SR, Miles RR, Patel JL, Abromowitch M, Lones MA, Cairo MS, Perkins SL (2014). Expression of Notch1 and mTOR Pathway Proteins in Pediatric Lymphoblastic Lymphoma; A Children’s Oncology Group Report. Journal of Hematopathology, 7(1), 9-14.
  • 22.Smock KJ, Schmidt RL, Hadlock G, Stoddard G, Grainger D, Munger MA (2014). Assessment of orally-dosed commercial silver nanoparticles on human ex vivo platelet aggregation. Nanotoxicology, 8(3), 328-33.

Professional Education

  • 1994-1998, BS, Utah State University (Biology) Logan, UT
  • 1999-2003, MD, University of Utah (Medicine) Salt Lake City, UT
  • 2003-2007, Resident, University of Utah (Pathology) Salt Lake City, UT
  • 2007-2008, Fellow, University of Utah (Hematopathology)Salt Lake City, UT